Fujirebio launches the automated Lumipulse® G AMH assay for accurate assessment of ovarian reserve

Fujirebio Europe announces the release of the Lumipulse G AMH assay for automated quantitative measurement of anti-Müllerian hormone in human serum or plasma.

Fujirebio Europe announces the release of the Lumipulse G AMH assay for automated quantitative measurement of anti-Müllerian hormone in human serum or plasma. This new assay is an important extension of the Lumipulse G fertility panel of biomarkers, already including LH, FSH, Testosterone, Progesterone, Prolactine, Estradiol, and bHCG. Lumipulse G AMH is based on a two-step immunoassay method for the LUMIPULSE G System and uses fully automated unique cartridge CLEIA technology.

“Anti-Müllerian hormone is an important aid for the assessment of ovarian reserve and for the prediction of the response to therapy in controlled ovarian stimulation.” said Christiaan De Wilde, CEO of Fujirebio Europe. “It was very important for us to answer customer requests and make this key assay available on our LUMIPULSE G platform. Our customers can now access fast testing for a broad spectrum of fertility markers with their automated and mono cartridge concept-based platforms.”